Search Results - "ELVIN, Paul"

The Cannabis Act : implications for human participant research with cannabis by Di Ciano, Patricia, Wickens, Christine, Paul, Elvin M, Mahmood, Raesham, Crépault, Jean-François, Rueda, Sergio, Boileau, Isabelle

“…In Canada, cannabis was legalized for medical purposes in 2001 and for nonmedical use in 2018, with edibles, concentrates, and topicals following in 2019 under…”
Get full text

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers by Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, Schellens, Jan H M

“…This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in…”
Get full text

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 by Green, Tim P., Fennell, Mike, Whittaker, Robin, Curwen, Jon, Jacobs, Vivien, Allen, Jack, Logie, Armelle, Hargreaves, Judith, Hickinson, D. Mark, Wilkinson, Robert W., Elvin, Paul, Boyer, Brigitte, Carragher, Neil, Plé, Patrick A., Bermingham, Alun, Holdgate, Geoffrey A., Ward, Walter H.J., Hennequin, Laurent F., Davies, Barry R., Costello, Gerard F.

“…AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive effects in vitro, and inhibited metastasis in a murine model of…”
Get full text

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer by ARCAROLI, John J, TOUBAN, Basel M, CHOON TAN, Aik, VARELLA-GARCIA, Marileila, POWELL, Rebecca W, ECKHARDT, S. Gail, ELVIN, Paul, DEXIANG GAO, MESSERSMITH, Wells A

“…To evaluate the efficacy of saracatinib (AZD0530), an oral Src inhibitor, in colorectal cancer (CRC) and to identify biomarkers that predict antitumor…”
Get full text

Nonclinical Selection Criteria for Maximizing Yield of Nucleic Acid Amplification Tests in Tuberculosis Diagnosis by HAN, Linda L, ELVIN, Paul, BERNARDO, John

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Estimated Costs of False Laboratory Diagnoses of Tuberculosis in Three Patients by Northrup, Jill M., Miller, Ann C., Nardell, Edward, Sharnprapai, Sharon, Etkind, Sue, Driscoll, Jeffrey, McGarry, Michael, Taber, Harry W., Elvin, Paul, Qualls, Noreen L., Braden, Christopher R.

“…We estimated direct medical and nonmedical costs associated with a false diagnosis of tuberculosis (TB) caused by laboratory cross-contamination of…”
Get full text

Abstract 3826: CCS1477, a potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro by Brooks, Nigel, Prosser, Amy, Young, Barbara, Gaughan, Luke, Elvin, Paul, Pegg, Neil

“…Abstract Background: CCS1477 is a potent and selective p300/CBP bromodomain inhibitor, currently in a Ph1 trial for patients with metastatic castration…”
Get full text

Abstract 1019: P300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumor AR and c-myc gene expression in vivo by Elvin, Paul, Pegg, Neil, Daminelli, Simone, Eden, Izabela, Young, Barbara, Prosser, Amy, Worthington, Jenny, Brooks, Nigel

“…Abstract Background: Histone acetyl transferases E1A binding protein (p300) and CREB binding protein (CBP) are known co-activators of several key transcription…”
Get full text

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response by Min, Ahrum, Jang, Hyemin, Kim, Seongyeong, Lee, Kyung-Hun, Kim, Debora Keunyoung, Suh, Koung Jin, Yang, Yaewon, Elvin, Paul, O'Connor, Mark J, Im, Seock-Ah

“…The androgen receptor (AR) is expressed in 60%-70% of breast cancers regardless of estrogen receptor status, and has been proposed as a therapeutic target in…”
Get full text

Abstract 3957: Analyzing the effects of radiotherapy on the metastatic phenotype: a role for combined therapeutic approaches incorporating Src and PI3K targeting by Rowling, Emily J., Telfer, Brian, Elvin, Paul, Williams, Kaye J.

“…Abstract Background: Radiotherapy is used in the treatment of over 50% of cancer patients. Although seen as a positive intervention, there are reports of…”
Get full text

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors by BASELGA, José, CERVANTES, Andres, SWAISLAND, Alan, IACONA, Renee, TABERNERO, Josep, MARTINELLI, Erika, CHIRIVELLA, Isabel, HOEKMAN, Klaas, HURWITZ, Herbert I, JODRELL, Duncan I, HAMBERG, Paul, CASADO, Esther, ELVIN, Paul

“…This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor saracatinib (AZD0530) in patients with…”
Get full text

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies by Platt, Adam, Morten, John, Ji, Qunsheng, Elvin, Paul, Womack, Chris, Su, Xinying, Donald, Emma, Gray, Neil, Read, Jessica, Bigley, Graham, Blockley, Laura, Cresswell, Carl, Dale, Angela, Davies, Amanda, Zhang, Tianwei, Fan, Shuqiong, Fu, Haihua, Gladwin, Amanda, Harrod, Grace, Stevens, James, Williams, Victoria, Ye, Qingqing, Zheng, Li, de Boer, Richard, Herbst, Roy S, Lee, Jin-Soo, Vasselli, James

“…To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer…”
Get full text

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer by Nam, Hyun-Jin, Im, Seock-Ah, Oh, Do-Youn, Elvin, Paul, Kim, Hwang-Phill, Yoon, Young-Kwang, Min, Ahrum, Song, Sang-Hyun, Han, Sae-Won, Kim, Tae-You, Bang, Yung-Jue

“…Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion,…”
Get full text

Regional copy number-independent deregulation of transcription in cancer by Stransky, Nicolas, Vallot, Céline, de Medina, Sixtina Gil Diez, Segraves, Rick, Asselain, Bernard, Spraggon, Carolyn, Allory, Yves, Albertson, Donna G, Abbou, Claude C, Thiery, Jean Paul, Southgate, Jennifer, Reyal, Fabien, Graham, Alexander, Bernard-Pierrot, Isabelle, Cassidy, Andrew, Chopin, Dominique K, Pinkel, Daniel, Radvanyi, François, de Rycke, Yann, Elvin, Paul

“…Genetic and epigenetic alterations have been identified that lead to transcriptional deregulation in cancers. Genetic mechanisms may affect single genes or…”
Get full text

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors by BERTOTTI, Andrea, BRACCO, Cecilia, GIROLAMI, Flavia, TORTI, Davide, GASTALDI, Stefania, GALIMI, Francesco, MEDICO, Enzo, ELVIN, Paul, COMOGLIO, Paolo M, TRUSOLINO, Livio

“…We examined whether inhibition of Src tyrosine kinase, a downstream effector of the MET oncogene, can hinder the malignant properties of gastric tumors…”
Get full text

Abstract LB-110: Expression of multiple androgen receptor splice variants in late stage prostate cancer by Ghazoui, Zara, Jones, Emma, Veldman-Jones, Margaret, Jacobs, Vivien N., Smith, Neil R., Johnstone, Michele, Barrett, J. Carl, Harrington, Elizabeth A., Elvin, Paul

“…Abstract The androgen receptor (AR) remains a key driver of disease progression even with the advent of new therapeutic agents such as abiraterone (A) and…”
Get full text

Abstract 2250: Combination of PARP inhibitor, Olaparib with pathway-targeted drug, vandetanib (Caprelsa™) in TNBC: A proof of principle study to determine the role of PI3K-AKT-mTOR or RAS-MAPK pathways in targeted drug-response by Dey, Nandini, Hui, Wu, Sun, Yuliang, Elvin, Paul, De, Pradip, Leyland-Jones, Brian

“…Abstract Introduction: Identification of the driving genetic alteration(s) (e.g. BRCA, PTEN) and deregulated signaling pathway(s) are critical for the…”
Get full text

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer by Kopetz, Scott, Morris, Van K, Parikh, Nila, Overman, Michael J, Jiang, Zhi-Qin, Maru, Dipen, Elvin, Paul, Gallick, Gary

“…The nonreceptor tyrosine kinase Src regulates multiple pathways critical to tumor proliferation, chemoresistance, and epithelial-to-mesenchymal transition. It…”
Get full text

Abstract 738: Increased Ret signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer by Gee, Julia M., Goddard, Lindy, Mottram, Huw J., Burmi, Rajpal S., Pumford, Sara L., Dutkowski, Carol M., Barrow, Denise, Hutcheson, Iain R., Nicholson, Robert I., Ellis, Ian O., Elvin, Paul

“…Abstract Deregulation of the tyrosine kinase Ret and its coreceptors (GFRα) has been implicated in neoplasia, and Ret is of interest as a therapeutic target in…”
Get full text

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers by Banerji, Udai, Dean, Emma Jane, Perez-Fidalgo, Jose Alejandro, Batist, Gerald, Bedard, Philippe L., You, Benoit, Westin, Shannon Neville, Kabos, Peter, Davies, Barry, Elvin, Paul, Lawrence, Peter, Yates, James W T, Ambrose, Helen, Rugman, Paul, Foxley, Andrew, Salim, Shaista, Casson, Ed, Lindemann, Justin P O, Schellens, Jan H. M.

“…Abstract only…”
Get full text